Rhabdomyolysis and statin therapy: Relevance to the elderly

American Journal of Geriatric Cardiology

Volumn 11, Issue 1, 2002, Pages 48-55

  Sica, Domenic A ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; DIGOXIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; STATIN; TACROLIMUS; WARFARIN;

ARTICLE; CELL DAMAGE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MARKETING; DRUG METABOLISM; DRUG WITHDRAWAL; ELDERLY CARE; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; MONOTHERAPY; MUSCLE CELL; MYOPATHY; POLYPHARMACY; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 0036143126     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2002.01422.x     Document Type: Article

References (75)

1. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)
2. Long-term safety of hepatic hydroxymethylglutaryl coenzyme A reductase inhibitors
3. The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins
4. Rhabdomyolysis and HMG-CoA reductase inhibitors
5. HMG-CoA reductase inhibitors and myotoxicity
6. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
7. Rhabdomyolysis associated with lovastatin and erythromycin use
8. Lovastatin and rhabdomyolysis
9. Drug-interaction-induced rhabdomyolysis
10. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin
11. Cytochrome P-450 3A4: Regulation and role in drug metabolism
12. Cholesterol lowering in the older population: Time for reassessment?
13. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
15. Age and gender bias ill stalin trials
16. Elderly patients at risk for coronary heart disease or stroke: Selecting an ideal product for lipid lowering
17. HMG-CoA reductase inhibitors in the prevention of stroke
18. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER)
19. CME Paper: Lipid lowering therapy is safe in the elderly: The LifeHelp 80-80 analysis
20. Comparative pharmacokinetics of lovastatin, simvastalin and pravastatin in humans
21. Clinical pharmacokinetics of pravaslatin: Mechanisms of pharmacokinetic events
22. Clinical pharmacokinetics of fluvastatin
23. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
24. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidemias
25. Clinical pharmacokinetics of cerivastatin
26. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s
27. Concomitant use of cytochrome P450 3A4 inhibitors and simvastalin
28. Metabolism of the new immunosuppressor cyclosporine G by human liver cytochromes P450
29. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs
30. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
31. CYP3A gene expression in human gut epithelium
32. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
33. Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporine
34. Postoperative management following heart transplantation
35. Severe rhabdomyolysis associated with tacrolimus
36. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
37. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
38. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
39. Statin-fibrate combination therapy
40. Cerivastatin and gemfibrozil-associated rhabdomyolysis
41. Fatal rhabdomyolysis caused by lipid-lowering therapy
42. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: Is the interaction predictable?
43. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
44. Lovastatin, nicotinic acid, and rhabdomyolysis
45. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia
46. Lovastatin. Warfarin interaction
47. Current perspectives on statins
48. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
50. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin
51. Polymyositis associated with simvastatin
52. Pravastatin-associated inflammatory myopathy
53. Efficacy and long-term adverse effect pattern of lovastatin
54. Drug-induced: Myopathies in man
55. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
56. Lovastatin-induced acute rhabdomyolysis
57. Drug-induced rhabdomyolysis - Mechanisms and management
58. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study
59. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
60. Efficacy and tolerability of simvastatin 20 mg vs. pravastatin 20 mg in patients with primary hypercholesterolemia
61. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
62. A multicenter, double-blind, one-year study comparing safety yard efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
63. Updated clinical safety experience with fluvastatin
64. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin
65. Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects
66. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia
67. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis
68. Lovastatin and elevated creatine kinase: Results of rechallenge
69. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day
70. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors: Focus on drug interactions
71. HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies
72. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes
73. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors
74. A review of clinical trials comparing HMG-CoA reductase inhibitors
75. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia